Harnessing the power of KISIMA® immunisation technology to discover and develop therapeutic vaccines
A novel approach to therapeutic vaccines
AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
First-in-class immunisation technology
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
Transforming the prospects of cancer patients
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
March 14-16, 2023 / Barcelona / Spain
Magali Dejob, Senior Protein Scientist, Stephane Costa Borges, Protein Research Associate, and Elodie Cuenot, Analytical Scientist, attending
May 9-12, 2023 / Amsterdam / The Netherlands
Keith Wilson, VP CMC and Manufacturing, speaking
May 3-5, 2023 / Mainz / Germany
Marie-Laure Santiago-Raber, Senior Director Non-Clinical Development, and Erika Riva, Scientist, attending